Abstract 501: Discovery of BPI-460372, a potent and selective inhibitor of TEAD for the treatment of solid tumors harboring Hippo pathway aberrations

Hongling Shen(Betta Pharmaceuticals (China)), Jiabing Wang(Betta Pharmaceuticals (China)), Hong Lan(Betta Pharmaceuticals (China)), Hongfei Rong(Betta Pharmaceuticals (China)), Jiayu Zhao(Chengdu University of Information Technology), Jinheng Gao(Betta Pharmaceuticals (China)), Xizhen Song(Betta Pharmaceuticals (China)), Zhengyao Zou(Betta Pharmaceuticals (China)), Yan Xu(University of California, Berkeley), Xiaofeng Xu(Hangzhou Normal University), Jin Guo(Guangxi University), Jie Chen(Air Force General Hospital PLA), Haibo Chen(Shanghai University), Hong Chen(Tongji Hospital), Yanju Liu(Betta Pharmaceuticals (China)), Xiaoyun Liu(Betta Pharmaceuticals (China)), Di Zhu(Chinese Academy of Sciences), Yabin Li(Betta Pharmaceuticals (China)), Xiangyong Liu(Betta Pharmaceuticals (China)), Lieming Ding(Betta Pharmaceuticals (China)), Jun Tong(Hangzhou Normal University), Xiangdong Zhao(Unknown), Xuepeng Ju(Betta Pharmaceuticals (China))
Cancer Research
April 4, 2023
10.1158/1538-7445.am2023-501
Cited by 11

Related Papers

Modulation of Rab GTPase function by a protein phosphocholine transferase
|Nature|2011|327
Advanced functional polymer materials
|Materials Chemistry Frontiers|2020|233
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
|The Lancet Respiratory Medicine|2021|183
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
|The Lancet Respiratory Medicine|2019|139
Acetylation of PHF5A Modulates Stress Responses and Colorectal Carcinogenesis through Alternative Splicing-Mediated Upregulation of KDM3A
|Molecular Cell|2019|127